Hologic, Inc. (NASDAQ:HOLX) – Equities research analysts at Jefferies Group cut their Q2 2018 EPS estimates for shares of Hologic in a report released on Wednesday. Jefferies Group analyst R. Denhoy now forecasts that the medical equipment provider will post earnings of $0.56 per share for the quarter, down from their previous estimate of $0.57. Jefferies Group currently has a “Buy” rating and a $49.00 target price on the stock. Jefferies Group also issued estimates for Hologic’s Q3 2018 earnings at $0.59 EPS, Q4 2018 earnings at $0.59 EPS, FY2018 earnings at $2.28 EPS, FY2019 earnings at $2.59 EPS and FY2020 earnings at $2.96 EPS.
HOLX has been the subject of a number of other research reports. Barclays PLC reiterated an “overweight” rating and set a $53.00 price objective (up previously from $50.00) on shares of Hologic in a research note on Monday, July 17th. BidaskClub lowered Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Stifel Nicolaus reiterated a “buy” rating on shares of Hologic in a research note on Friday, July 14th. Bank of America Corporation reiterated a “neutral” rating and set a $48.00 price objective (up previously from $44.00) on shares of Hologic in a research note on Friday, July 21st. Finally, Canaccord Genuity reiterated a “buy” rating and set a $53.00 price objective on shares of Hologic in a research note on Tuesday, May 9th. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $48.64.
ILLEGAL ACTIVITY NOTICE: “Equities Analysts Offer Predictions for Hologic, Inc.’s Q2 2018 Earnings (HOLX)” was first posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/equities-analysts-offer-predictions-for-hologic-inc-s-q2-2018-earnings-holx-updated.html.
Hologic (NASDAQ HOLX) traded down 0.56% during mid-day trading on Monday, reaching $38.81. The company’s stock had a trading volume of 1,147,624 shares. The stock has a 50-day moving average price of $45.06 and a 200-day moving average price of $42.98. The company has a market capitalization of $10.89 billion, a price-to-earnings ratio of 14.45 and a beta of 0.90. Hologic has a one year low of $35.15 and a one year high of $46.80.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The company had revenue of $806.10 million during the quarter, compared to analyst estimates of $799.70 million. During the same quarter in the previous year, the company posted $0.51 earnings per share. Hologic’s revenue was up 12.4% compared to the same quarter last year.
A number of large investors have recently bought and sold shares of HOLX. State Street Corp boosted its stake in Hologic by 1.5% in the first quarter. State Street Corp now owns 12,710,718 shares of the medical equipment provider’s stock valued at $540,846,000 after buying an additional 189,572 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Hologic by 23.7% in the second quarter. Victory Capital Management Inc. now owns 5,012,352 shares of the medical equipment provider’s stock valued at $227,461,000 after buying an additional 961,528 shares during the last quarter. Bank of Montreal Can boosted its stake in Hologic by 6.6% in the second quarter. Bank of Montreal Can now owns 3,418,319 shares of the medical equipment provider’s stock valued at $155,123,000 after buying an additional 211,550 shares during the last quarter. American Century Companies Inc. boosted its stake in Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock valued at $134,668,000 after buying an additional 2,204,085 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Hologic by 6.4% in the first quarter. Geode Capital Management LLC now owns 3,116,366 shares of the medical equipment provider’s stock valued at $132,440,000 after buying an additional 186,854 shares during the last quarter. Institutional investors own 94.46% of the company’s stock.
In related news, insider Peter J. Valenti III sold 10,005 shares of Hologic stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $43.44, for a total value of $434,617.20. Following the sale, the insider now directly owns 20,994 shares in the company, valued at approximately $911,979.36. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Lawrence M. Levy sold 9,837 shares of Hologic stock in a transaction dated Wednesday, May 10th. The stock was sold at an average price of $45.34, for a total value of $446,009.58. Following the completion of the sale, the director now owns 40,577 shares in the company, valued at $1,839,761.18. The disclosure for this sale can be found here. Over the last quarter, insiders sold 70,464 shares of company stock worth $3,078,921. 0.79% of the stock is currently owned by insiders.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.